The long-term efficacy of sodium–glucose cotransporter 2 (SGLT-2) inhibitors in managing type 2 diabetes mellitus (T2DM) extends beyond glycemic control, with growing evidence supporting their role in reducing long-term cardiovascular and renal complications. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.